Opinion
Video
Emerging Therapies: a look at the current data: NefIgArd study
Author(s):
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.
- In the phase 3 ALIGN trial (NCT04573478), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Related Videos
Related Content
